Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 1, 2010, Pages 79-90

  Ezat, Wan Puteh Sharifa ^a   Aljunid, Syed ^b  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b UKM Medical Centre   (Malaysia)

Author keywords

Cervical cancer; Cost effectiveness; HPV vaccination; Pap smear; Quality of life

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; ECONOMICS; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALAYSIA; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PHARMACOECONOMICS; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; MALAYSIA; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77955800775     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Abridged Life Tables: Malaysia 2002-2005 (2006). Department of Statistics Publisher; Malaysia.
2. Annual Report, Department of Statistics (2006). Malaysia.
3. Annual Report, Department of Statistics (2009). Malaysia.
4. Anttila T, Saikku P, Koskela P, et al (2001) Serotypes of Chlamydia Trachomatis and risk for development of cervical squamous cell carcinoma. JAMA, 285, 47-56.
5. Azman AB, Low LL, Rugayah B, et al (2003). Quality of life of the Malaysian general population: results from a postal survey using the SF-36. Med J Malaysia, 58, 101--21.
6. Azman AB, Low LL, Rugayah B, et al (2005). Validity and reliability of the SF 36: the Malaysian context. Med J Malaysia, 60, 70-87.
7. Baade PA, Fritschi L, Eakin EG (2006). Non-cancer mortality among people diagnosed with cancer. Cancer Causes Control, 17, 287-97.
8. Balasubramani L, Tidy J (2006). Hope for cervical cancer screening. Hospital Doctor, Pg 26-29.
9. Brown RE, Breugelmans JG, Theodoratou D, Benard S (2006). Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Current Med Res Options, 22, 663-71.
10. Centers for Disease Control and Prevention (1999). Prevention of genital HPV infection and sequelae: report of an external consultants' meeting. Division of STD Prevention. Georgia US.
11. Clifford GM, Gallus S, Herrero R, Munoz N (2005). Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 366, 991-9.
12. Department of Health and Human Services, Centers for Disease Control and Prevention. (2007). Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report. 56.
13. Ferenczy A, Coutlee F, Franco E, Hankins C (2003) Human Papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. Can Med Assoc J, 169, 431-43.
14. FIGO Committee on Gynecologic Oncology (2003). IGCS Guidelines Committee. Staging classifications and clinical practice guidelines of gynecologic cancers. 2nd edition. Pg. 36-40. http://www.figo.org/content/PDF/satging-booklet.pdf (22nd July 2007)
15. Goldie SJ, Kohli M, Grima D, et al (2004). Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst, 96, 604-15.
16. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A (2005). Cost-effectiveness of cervical cancer screening in five developing countries. New Engl J Med, 353, 2158-69.
17. Greenwald HP, McCorkle R (2007). Remedies and life changes among invasive cervical cancer survivors. Urol Nursing, 27, 47-53.
18. Hakama M, Luostarinen T, Hallmans G, Jellum E (2000). Joint effect of HPV 16 with Chlamydia Trachomatis and smoking on risk of cervical cancer: antagonism or misclassification. Cancer Causes Control, 11, 783-92.
19. Herck PV, Vanhaecht K, Sermeus W (2004). Effects of clinical pathways: do they work? J Integrated Care Pathways, 8, 95-105.
20. Jamsiah M, Shamsul AS, Aniza I, et al (2008). Amalan calitan pap and faktor hubungkait di kalangan wanita berkahwin di Kg. Sesapan Kelubi, Hulu Langat Selangor Malaysia. Malay J Commun Hlth, 14, 52-61.
21. Joura EA, Leodolter S, Hernandez-Avilla M, et al (2007). Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet, 369, 1693-702.
22. Kim JJ, Wright TC, Goldie SJ (2005). Cost effectiveness of Human Papillomavirus DNA testing in the United Kingdom, Netherlands, France and Italy. J Natl Cancer Inst, 97, 888-95.
23. Malaysian National Cancer Registry Report (2003). Ministry of Health, Malaysia.
24. Maissi E, Marteau TM, Hankins M (2005). The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6 months follow up. Br J Cancer, 92, 990-4.
25. Mallock NA, Braithwaite J (2005). A template for clinical pathway design based on international evidence. Clin Governance Bulletin, 5, 2-6.
26. Mandelblatt JS, Lawrence WF, Gaffikin L, et al (2002). Costs and benefit of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst, 94, 1469-76.
27. Markowitz LE, Dunne EF, Saraiya M, et al (2007). Quadrivalent human hapillomavirus vaccine. recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity Mortality Weekly Report, 56, 1-23.
28. Ministry of Health (2006). Annual Report. Publisher Ministry of Health, Malaysia.
29. Morantz CA (2006). ACOG releases guidelines for management of abnormal cervical cytology and histology. Am Fam Phys, 73, 719-23.
30. Nik Ibrahim NS (2005). Cost effectiveness of Pap Smear screening in cervical cancer screening. Doctorate Thesis. Universiti Kebangsaan Malaysia.
31. Nurhayati ZA, Yadav M, Daniels JM, et al (1994). Association of human papillomavirus with pre invasive and invasive cervical carcinoma. Malay J Sci, 15A, 49-57.
32. Othman NH, Devi BCR, Halimah Y (2009). Cervical cancer screening: patients' understanding in major hospitals in Malaysia. Asian Pac J Cancer Prev, 10, 569-74
33. Peto J, Gilham C, Fletcher O, et al (2004). The cervical cancer epidemic that screening has prevented in the UK. Lancet, 364, 249-56.
34. Reich M, Lesur A, Perdrizet-Chevallier C (2008). Depression, quality of life and breast cancer. Breast Cancer Res Treat, 110, 9-17.
35. World Health Organization (2005). Sexual and Reproductive Health of Adolescents and Youths in Malaysia. A review of literatures and projects.
36. Sharifa Ezat WP, Syed MA, Paul N, et al (2009). Quality of life among preinvasive and invasive cervical cancer in Malaysia. ASEAN J Psychiatry, 10, 115-26.
37. Sharifa Ezat WP, Paul N, Syed MA (2008). Economic burden of cervical cancer in Malaysia. Med J Indonesia, 17, 272-80.
38. Sherlaw-Johnson C, Gallivan S, Jenkins D (1997). Evaluating cervical cancer screening programs for developing countries. Int J Cancer, 72, 210-6.
39. Spitzer M, Apgar BS, Brotzman GL (2006). Management of histologic abnormalities of the cervix. Am Fam Phys, 73, 105-15.
40. Third National Health and Morbidity Survey (2006). http://www.nih.gov.my/NHMS/ (13th August 2009).